구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | oxycodone hydrochloride (oxycodone hydrochloride) Ensysce Biosciences·Brain and Central Nervous System T… 61 trials |
|---|---|
Overview Program | oxycodone hydrochloride |
Overview Company | Ensysce Biosciences |
Overview Modality | CGT |
Overview Target | Brain and Central Nervous System Tumors |
Overview Indication | Brain and Central Nervous System Tumors; Chronic Myeloproliferative Disorders |
Overview Phase | PRECLINICAL |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
PK/PD Species | Rat, Human |
PK/PD Animal (cat.) | Human, Rat |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Rat, Human |
Toxicology Animal (cat.) | Human, Rat |
Toxicology Major finding | Comparison of oxycodone hydrochloride injection versus sufentanil for postoperative analgesia in patients undergoing minimally invasive cardiac valve replacement: study protocol for a single-centre, randomised, double-blind non-inferiority trial.. With the advancement of the ERAS (Enhanced Recovery After Surgery) concept, minimally invasive heart valve replacement surgery has become widely perform… |
Clinical Safety signal | Comparison of oxycodone hydrochloride injection versus sufentanil for postoperative analgesia in patients undergoing minimally invasive cardiac valve replacement: study protocol for a single-centre, randomised, double-blind non-inferiority trial.. With the advancement of the ERAS (Enhanced Recovery After Surgery) concept, minimally invasive heart valve replacement surgery has become widely perform… |
Clinical Selected reported efficacy | ORR 13.7% |
Clinical Reported ORR | 13.7% |
Clinical Result source | ClinicalTrials.gov NCT00386243 |
Clinical Program phase | PRECLINICAL |
Clinical Trial ref | NCT00386243 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | oxycodone hydrochloride (oxycodone hydrochloride) Ensysce Biosciences·Brain and Central Nervous System T… 61 trials |
|---|---|
Overview Program | oxycodone hydrochloride |
Overview Company | Ensysce Biosciences |
Overview Modality | CGT |
Overview Target | Brain and Central Nervous System Tumors |
Overview Indication | Brain and Central Nervous System Tumors; Chronic Myeloproliferative Disorders |
Overview Phase | PRECLINICAL |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
PK/PD Species | Rat, Human |
PK/PD Animal (cat.) | Human, Rat |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Rat, Human |
Toxicology Animal (cat.) | Human, Rat |
Toxicology Major finding | Comparison of oxycodone hydrochloride injection versus sufentanil for postoperative analgesia in patients undergoing minimally invasive cardiac valve replacement: study protocol for a single-centre, randomised, double-blind non-inferiority trial.. With the advancement of the ERAS (Enhanced Recovery After Surgery) concept, minimally invasive heart valve replacement surgery has become widely perform… |
Clinical Safety signal | Comparison of oxycodone hydrochloride injection versus sufentanil for postoperative analgesia in patients undergoing minimally invasive cardiac valve replacement: study protocol for a single-centre, randomised, double-blind non-inferiority trial.. With the advancement of the ERAS (Enhanced Recovery After Surgery) concept, minimally invasive heart valve replacement surgery has become widely perform… |
Clinical Selected reported efficacy | ORR 13.7% |
Clinical Reported ORR | 13.7% |
Clinical Result source | ClinicalTrials.gov NCT00386243 |
Clinical Program phase | PRECLINICAL |
Clinical Trial ref | NCT00386243 |
추천 비교
추천 비교